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Introduction
Hydrophilic matrix tablets are among the 
most popular orally administered controlled 
release systems. Despite having been around 
since four decades, matrices are still the 
reference starting point for innovations in drug 
delivery. It can be due to the fact that they are 
considered quite reliable in terms of drug 
delivery, simple technology, and low cost of 
manufacture. Moreover, matrices that can be 
continuously innovated as new materials for 
formulation became commercially available (1-
5). 
The matrix tablets are usually composed of 
active pharmaceutical ingredients (APIs) and 
hydrophilic swellable polymers. When the 
system is exposed to the aqueous medium, water 
will be absorbed and a gel layer will be formed. 
This viscous gel layer may hinder water 
penetration and become the rate-controlling step 
during gel formation. The gel strength is 
important in the matrix performance and is 
dependent on the chemical structure, 
concentration, and viscosity of the polymer used. 
Depending on the mechanical properties of the 
gel layer, drug release is controlled by different 
mechanisms and kinetics. Polymer swelling, 
drug dissolution, drug diffusion, and matrix 
erosion are the basic phenomena leading to the 
drug release from swellable matrices (6–12). 
Additionally, drug load and solubility can 
influence the release mechanism and kinetics. 
Hydroxy propyl methyl cellulose (HPMC) is 
propylene glycol ether of methylcellulose and is 
widely used as a matrix former in oral controlled 
release tablet formulations (1). One of its most 
important characteristics is the high swell ability, 
which has a significant effect on the release 
kinetics of an incorporated drug. Furthermore, 
HPMC is compatible with numerous drugs, 
accommodates high levels of drug loading, and 
can be easily incorporated to form matrix tablets 
by direct compression or granulation (9, 13–16). 
The availability of a wide range of viscosity 
grades also allows the formulator to modify the 
release of drugs from HPMC matrix tablets 
according to therapeutic need.  
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High molecular weight poly (ethylene 
oxides) (PEOs) have been proposed as an 
alternative to HPMC in controlled release 
dosage forms (17). They are important polymers 
for the pharmaceutical industries mainly because 
of their non-toxicity, high water solubility and 
swell ability, insensitivity to the pH of the 
biological medium, and ease of production. 
PEOs swell and form a compact gel layer on the 
surface of the tablet which is responsible for the 
controlled drug release (17-22). They are also 
available in a wide range of molecular weights, 
thus allowing the formulator to control the 
mechanism of drug release to achieve the 
therapeutic goal. 
Meropenem (MEX) is a synthetic broad 
spectrum antibacterial drug being the firstly 
selected drug for the treatment of diseases 
caused by Campylobacter, E. coli, Salmonella, 
Shigella, and V. cholera (23, 24). The drug is 
also used for the treatment of urinary tract 
infections as well as gonorrhea and infection of 
eyes (23). The recommended dosage is usually 
400 mg twice daily. The half-life of MEX in 
serum and plasma is 3-4 hours and only 
approximately 30–40% of an oral dose is 
absorbed (25, 26). Increasing bacterial resistance 
to currently available antibiotics, including the 
quinolone class, has reduced their effectiveness, 
making the therapeutic decisions more difficult, 
and may compromise future use of this class of 
drugs (27–31).  
The development of an extended-release 
formulation that could improve the 
bioavailability of MEX and reduce the 
administration schedule may improve the 
patients’ comfort and compliance, resulting in 
lower discontinuation of the therapy, with 
consequently a decrease in bacterial resistance. 
The correct choice of the hydrophilic polymer, 
molecular weight, and quantity in the matrix 
formulation can provide an appropriate 
combination of polymer swelling, erosion, or 
drug diffusion mechanisms to control drug 
release. Thus, the aim of this work was to 
develop and carry out stability and in vitro 
dissolution studies of a new formulation of 
meropenem extended-release tablets. 
2. Materials and methods 
2.1. Materials 
Meropenem (MEX) was purchased from 
Cadilla Pharmaceuticals (Mumbai, India). 
Hydroxy-propylmethylcellulose (HPMC) 
K100LV (apparent viscosity: 100 mPa s, 2% in 
water at 20°C), HPMC K4M (4000mPa s), poly 
(ethylene oxide) (PEO) N60K (2000 kDa), and 
PEO 301 (4000 kDa) were kindly donated by 
Colorcon (Banglore, India). The pharmaceutical 
excipients used were microcrystalline cellulose 
(Microcel 102, Blanver, Itapevi, India), 
magnesium stearate and colloidal silicon dioxide 
(SD fine, Mumbai, India). 
2.2. Methods 
2.2.1. Preparation of Matrix Tablets. A 
powder blend containing 
Table 1 Composition of tablets containing hydroxypropylmethyl cellulose (HPMC) or poly (ethylene 
oxide) (PEO) 
Composition For one tablet For one tablet 





PEOWSR 301  
20% 30% 
Magnesium stearate 1% 1% 
Colloidal silicon dioxide 0.5% 0.5% 
Microcrystalline cellulose q.s. q.s. 
Total weight 1.07 g 1.07 g 
MEX, polymer, and microcrystalline cellulose 
was prepared and mixed for 15 min, followed by 
addition of magnesium stearate and colloidal 
silicon dioxide with a further 5 min mixing. The 
modules having the composition reported in 
Table 1 were prepared by direct compression 
using a 19 × 8mm punch set (Fellc compressing 
model F-10/8). 
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2.2.2. Characterization of Tablet 
Formulation.  
Tablets were characterized by weight, 
hardness, friability, dimension, and loss on 
drying according to pharmacopeial limits (32, 
33). The average weight was obtained for at least 
20 units. Hardness was determined for at least 10 
tablets using a Hardness Tester (298-AT) and 
adopting a minimum hardness of 3 kgF as the 
acceptance criterion. For each formula, friability 
was evaluated for a sample of 20 tablets, using 
the acceptance criterion of a maximum loss of 
1.5% of the initial weight. Dimension was 
evaluated measuring 10 tablets with a 
paquimeter. Loss on drying was carried out with 
2 g of sample, in vacuum, at 105°C for 2 h. 









 Uncoated Coated Uncoated Coated Uncoated Coated  
HPMC K100LV 
20%  
1.1154 1.1472 16.3 17.0 7.75 7.29 0.021 
HPMC K100LV 
30%  
1.1025 1.1321 14.8 16.4 7.93 7.60 0.014 
HPMC K4M 20%  1.1033 1.1314 13.1 15.1 7.08 6.60 0.034 
HPMC K4M 30% 1.0795 1.1119 13.0 14.5 7.29 7.11 0.018 
PEO N60K 20%  1.0858 1.1193 14.2 15.7 7.02 5.08 0.017 
PEO N60K 30%  1.0854 1.1131 16.9 17.7 6.77 5.64 0.021 
PEO 301 20%  1.0831 1.1162 16.6 18.8 7.16 6.91 0.018 
PEO 301 30%  1.1014  1.1306  16.0  17.5  7.09  7.01  0.023 
a
Mean of twenty determinations; 
b
mean of ten determinations. 
2.2.3. Tablet Coating and Blistering.  
A tablet coating solution was formed by 
adding 30 g of Opadry II White to 120 g of 
purified water and stirring for 2 min. An amount 
corresponding to 50% of each formulation batch 
was placed in a Rama Cota RD conventional 
coating machine. Tablets were preheated until 
the bed temperature reached 45°C. Pan rotation 
was set to 40 rpm, and tablets were coated using 
a Binks Model 460 spray gun operating at a 
pressure of 2 bar. The coating solution was 
pumped at a rate of 5.9–9.6 g/min using a 
peristaltic pump. Tablet bed temperature was 
maintained between 42 and 45°C during the 
spray coating process. After coating, an amount 
of coated and uncoated tables were blistered in 
transparent PVC blister and sealed with an 
aluminium foil. 
2.2.4. MEX Tablets Assay  
MEX quantification assay was carried out 
according to a previously validated method
34
. 
Briefly, the LC system was operated 
isocratically at 40°C using a mobile phase 
composed by phosphoric acid 0.04M, pH 
3.0/acetonitrile (84 : 16; v/v), eluted at a flow 
rate of 1.0 mL/min. A reversed-phase 
Phenomenex (Torrance, USA) Luna C18 column 
(150mm × 4.6mm I.D., with a particle size of 5 
𝜇m and pore size of 100 ˚ A) was used, and the 
detector was set at 272 nm. The injection volume 
was 20 𝜇L. 
To prepare the sample stock solution, the 
manufactured extended-release tablets were 
crushed to a fine powder. An appropriated 
amount was transferred into an individual 50mL 
volumetric flask, dissolved with 0.2 mL of 
glacial acetic acid, and diluted to volume with 
mobile phase, obtaining a concentration of 
1mg/mL of the API. The MEX standard stock 
solutions were prepared by weighing 50mg, 
transferred to 50mL volumetric flasks, dissolved 
with 0.2mL of acetic acid glacial, and diluted to 
volume with mobile phase, obtaining a 
concentration of 1mg/mL. Both sample and 
standard stock solutions were stored at 2–8°C 
protected from light. Working solutions were 
prepared daily by diluting the stock solutions to 
an appropriate concentration in mobile phase.  
2.2.5. Stability Tests  
The manufactured tablets were submitted to 
accelerated stability test. Samples of each batch 
(noncoated, coated, with and without blister) 
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were maintained for 6 months in an accelerated 
stability chamber at 40 ±2°C and 75 ±5% 
relative humidity (35, 36). For photo stability 
tests, samples were exposed to an overall 
illumination of not less than 1.2 million lux (37) 
The illumination was measured with a Digital 
Lux Meter. Protected samples (wrapped in 
aluminium foil) were used as dark controls to 
evaluate the contribution of thermally induced 
change to the total observed change. 
Table 3 Assay Results of Accelerated Stability Test 
Formulation Time zero After 6 months 













HPMC K100LV 20%  101.98  101.09  101.16  101.51  102.03  101.18 
HPMC K100LV 30%  101.47  101.81  101.87  103.01  100.87  101.74 
HPMC K4M 20%  101.45  100.42  100.44  102.98  101.92  101.08 
HPMC K4M 30% 100.88  99.31  99.12  99.45  99.91  98.09 
PEO N60K 20%  102.06  101.72  102.89  98.47  101.44  100.26 
PEO N60K 30%  99.43  99.92  98.49  99.05  99.44  99.03 
PEO 301 20%  99.48  99.35  101.24  97.51  101.75  100.31 




Figure 1. Meropenem blistered matrix tablets 
after photo-stability study: uncoated (a) and 
coated (b). 
2.2.6. Drug Release Study  
Drug release studies were performed based on 
pharmacopeial methods using USP apparatus II 
Vankel 7000 dissolution tester (Varian 
Technology Group, Cary, USA), with paddle 
rotation of 75 rpm, in 900 mL of buffer pH 4.0 at 
37.0±0.5°C (32, 33). At specified time intervals, 
5mL samples were withdrawn, filtered, and 
quantified in a UV spectrophotometer (Varian 
Cary 50 bio, Cary, USA) at the wavelength 278 
nm. 
2.2.7. Analysis of Drug Release  
The analysis of the values obtained in 
dissolution tests is easier when mathematical 
formulas that express the dissolution results as a 
function of some of the dosage forms 
characteristics are used. MEX release kinetic 
was evaluated according to the following 
models: zero order, first order, Higuchi, and 
Korsmeyer- Peppas. Additionally, the difference 
factor (𝑓1) and similarity factor (𝑓2) were used to 
compare the dissolution profiles. 
Zero-Order Model 
Drug dissolution from pharmaceutical dosage 
forms that do not disaggregate and release the 
drug slowly (assuming that area does not change 
and no equilibrium conditions are obtained) 
following a “steady-state release” can be 
represented by eq.(1) (38): 
 
Where 𝑄𝑡 is the fraction of drug released at time 
𝑡; 𝑄0 is the initial amount of drug in the solution 
(most times 𝑄 0 = 0); 𝑘 0 is the zero-order 
release constant. The pharmaceutical dosage 
forms following this profile release the same 
amount of drug by unit of time, and it is the ideal 
method of drug release in order to achieve a 
pharmacological prolonged action. 
First-Order Model 
The drug dissolution is assumed to decline 
exponentially, and the release rate is 
proportional to the residual amount of drug in 
the dosage form eq.(2) (38): 
 
Where 𝑄𝑡 is the fraction of drug released at time 
𝑡; 𝑄0 is the initial amount of drug in the solution; 
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𝑘1 is the first-order release constant. The 
pharmaceutical dosage forms following this 
dissolution profile release the drug by unit of 
time in a way that is proportional to the amount 
of drug remaining in its interior. 
Higuchi Model 
It is the most widely used model to describe drug 
release from matrices, which is derived from 
Higuchi for a planar matrix. It describes the drug 
release mechanism as a diffusion process based 
on Fick’s law, dependent on the square root of 
time in eq. (3) (38, 39): 
 
Where 𝑄𝑡 is the fraction of drug released at time 
𝑡 and 𝐾𝐻 is the Higuchi dissolution constant. 
Korsmeyer-Peppas Model 
This model is generally used to analyze the 
release of pharmaceutical polymeric dosage 
forms when the release mechanism is not well 
known or when more than one type of release 
phenomena could be involved in eq.(4) (38, 40): 
 
Where 𝑀𝑡/𝑀∞ is the fraction of drug released, 𝑘 
is the kinetic constants characteristic of the 
drug/polymer, Ƞ is the diffusional exponent for 
drug release. Dissolution values in the range of 
5–60% were used to fit release data. 
Difference Factor (f1) and Similarity Factor 
(f2) 
The relevance of the difference between the 
release curves were assessed using difference 
factor f1 and similarity factor f2, calculated by (5) 
and (6), respectively (41, 42): 
 
An f1 value up to 15 (0–15) and f2 value between 
50 and 100 implies similarity between two 
release profiles. Only one more point after the 
85% of drug has been released was used for the 
equation.  
3. Results and discussion 
Meropenem matrix tables were successfully 
obtained by direct compression. Different 
polymers and molecular weights did not 
interfere in the technological process. The 
pharmacopeial characteristics of the 
manufactured tablets are summarized in Table 2. 
These results demonstrated that the tablets were 
reliable on hardness and friability, which are 
important characteristics for the further step of 
coating. 
Consistent hardness of the tablet surface 
enables the coating to “lock” into the surface. If 
the surface is too soft, the impingement of the 
solution can erode the tablet. Too hard a surface 
will not allow the solution to impinge and 
adhere, and the coating will peel away. Both of 
these coating defects can also occur by over- or 
under applying the coating solution or by 
applying the coating with too much or too little 
force (43-46). The film-coating (Opadry II) 
applied on the MEX tablets surface is 
nonfunctional; however, it can improve the final 
quality by protecting the hygroscopic polymer 
from absorbing humidity and preventing photo-
degradation of the drug. MEX coated tablets 
showed a uniform, smooth, and shiny surface, 
without coating defects. From Table 2, it can be 
observed that the weight and hardness increased 
about 3% and 9%, respectively, demonstrating 
the influence of the coating process. The loss on 
drying analysis (Table 2) showed that the coated 
tablets have a lower amount of volatile matter, 
probably due to the loss of water absorbed 
during the coating process at 42–45°C.  
The assay determination of MEX 
demonstrated that all formulations were in the 
range from 99.43 to 102.35% (Table 
3).Therefore, the coating process did not 
influence the assay of the drug.  
Accelerated stability testing was carried out 
to provide evidence of how the quality of the 
manufactured tablets may change with time 
under the influence of environmental factors 
such as temperature and humidity. Brazil, being 
considered with hot and humid climate, is 
classified in region IV (35). According to this 
classification, the accelerated stability study was 
carried out for 6 months in a climatic chamber at 
40±2°C and 75±5% relative humidity. The 
obtained results are shown in Table 3. All 
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formulations were considered stable since after 6 
months a change from the initial assay of 5% or 
more was not observed (35). The presence of 
coating and/or blister did not influence the 
stability of the developed tablets. Additionally, 
the chromatographic profiles did not show any 
additional degradation peak. 
Light testing should be an integral part of 
stress testing and recommends evaluation of the 
photo stability of a formulation to demonstrate 
that light exposure does not result in 
unacceptable changes (35, 37). For this study, 
the following formulations were selected: 
HPMC K100LV (20 and 30%) and PEO N60K 
(20 and 30%). At the end of the exposure period 
(about five days), equivalent of not less than 1.2 
million lux, samples were examined for changes 
in appearance and for assay. A color change 
from pale-yellow to dark-yellow in MEX raw 
material and uncoated tablets was observed. The 
transparent blister (primary packing) did not 
have any protecting influence on the 
formulations (Figure 1). Prolonged exposure of 
MEX bulk drug, tablets, and specially in solution 
under direct sunlight or fluorescent light results 
in the formation of ethylenediamine degradation 
product (47, 48). Since the chromatograms did 
not show additional peaks and a significant 
decrease of drug content was not observed 
(assays between 98.17 and 100.80%), it seems 
that the ethylene diamine degradant requires an 
exposure time and/or intensity higher than the 
used in this research to be significantly formed. 
Nonetheless, to prevent drug exposure to light 
and degradation, the coating process or light-
protective blister for the formulations would be 
recommended. 
Two concentrations (20 and 30%) of 
different MWs HPMC or PEO polymers were 
used to manufacture the MEX matrix tablets 
used in this study (Table 1). The dissolution test 
was carried out under sink conditions, defined as 
the volume of medium being at least three times 
higher than that necessary to obtain a saturated 
solution of the drug (32). Samples were 
withdrawn from the dissolution medium at the 
following times: 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 
11, 12, and 24 h. The first time point at 0.5 h 
was included to study if the product presents a 
burst effect (with an excessive early drug 
release), while the final time point shows 
whether or not the intended dose is fully 
delivered. MEX is an amphoteric drug with 
minimal solubility in water at pH between 4.0 
and 10.0. This way, the dissolution studies were 
carried out in buffer pH 4.0 as described in the 
U.S. Pharmacopoeia (glacial acetic acid and 
sodium hydroxide) for MEX tablets (32). In 
addition, further information could be obtained 
during the formulation development step by 
carrying out dissolution studies in gastric and 
intestinal simulated fluids.  
MEX release profiles are shown in Figures 
2-5. The polymers used have different average 
MWs, and therefore they differ in controlling 
drug release from matrix tablets. An extended-
release of MEX was obtained for all 
formulations manufactured, demonstrating that 
the mechanical strength of the viscous-gel layer 
was strong enough to maintain its integrity and 
drug release. Faster dissolution was obtained for 
formulations containing lower MW polymer and 
concentration (20%) (Figures 2 and 4). The 
tablets containing HPMC K100LV showed the 
fast dissolution profile, with complete drug 
release at about 6–8 h (Figure 2).  For the 
formulations containing HPMC K4M (Figure 3) 
and PEO 301 (Figure 5), the MEX release could 
be considered complete only at 24 h. Due to the 
high MW and/or concentration of polymer in the 
formulations, the swelling was slow and the gel 
strength was very high, resulting the central part 
of the tablet not being fully wetted or hydrated (a 
“dry core”), with slow drug release. It was 
particularly notable for the formulations 
containing 30% of these polymers.  
It seems that the coating process somehow 
influenced the MEX dissolution profile (Figures 
2–5), and a relation with the polymer MW could 
be suggested. In general, coated formulations 
exhibited faster drug release than uncoated ones. 
The faster MEX release may be due to the 
coating process temperature that resulted in 
lower residual humidity tablets (Table 2) and 
consequently a faster water uptake and polymer 
swelling in the dissolution medium. 
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Figure 2 Meropenem released versus time of matrix tablets containing HPMC K100LV. 
 
Figure 3 Meropenem released versus time of matrix tablets containing HPMC K4M. 
 
Figure 4 Meropenem released versus time of matrix tablets containing PEO N60K. 
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Figure 5 Meropenem released versus time of matrix tablets containing PEO 301. 
For HPMC K100LV formulations, due to the 
lower MW, water uptake, polymer hydration, 
and gelification is faster than dissolution of the 
coating film. In this case, the coating may have 
worked as a “barrier,” and drug release was 
delayed. For PEO301 the dissolution profiles 
were overlapped, demonstrating no influence of 
the coating. It can be explained since high MW 
polymers form a stronger gel layer, with lower 
water uptake rate and drug release, hence 
influencing drug diffusion and dynamics 
ofmatrix erosion. However, the influence of the 
coating process was not relevant based on the 
difference (f1) and similarity (f2) parameters 
calculated (Table 4). 
Table 4 Difference Factor (𝑓1) And Similarity Factor (𝑓2) Calculated For Uncoated And Coated 
Meropenem Matrix Tablets 
Formulation 𝑓1 𝑓2 
HPMC K100LV 20%  5.47 71.72 
HPMC K100LV 30% 8.50 62.32 
HPMC K4M 20%  9.22 70.03 
HPMC K4M 30% 14.23 66.36 
PEO N60K 20%  13.77 56.35 
PEO N60K 30% 14.66 57.81 
PEO 301 20%  2.00 91.85 
PEO 301 30%  3.12 88.95 
Dissolution profiles were analyzed for zero-
order, first order, and Higuchi models with the 
equations up to 12 h Table 4: Difference factor 
(f1) and similarity factor (f2) calculated for 
uncoated and coated meropenem matrix tablets. 
of drug release, except for HPMC K100LV 20 
and 30% formulations where the equations were 
analyzed for up to 6 and 8 h, respectively. The 
analysis according to Korsmeyer- Peppas was 
carried out with the diffusional exponential 
equation up to 60% of drug released
40
. 
Calculation of the exponent identifies the 
prevalent mechanism of release. For cylindrical 
systems, Ƞ = 0.45 indicates diffusion controlled 
(Fickian) drug release, and Ƞ = 0.89 indicates 
swelling/erosion-controlled drug release (case-II 
transport). Values of Ƞ between 0.45 and 0.89 
can be regarded as an indicator for the 
superposition of both phenomena, indicating that 
the drug delivery was not controlled only by 
diffusion but also by significant polymer 
relaxation or erosion mechanisms (anomalous 
transport). The Ƞ > 0.89 values reveal a super 
case-II transport. This mechanism could result 
from an increased plasticization at the relaxing 
boundary (gel layer) and is also related to 
polymer relaxation and erosion mechanisms (40, 
49, 50).  
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In general, data of all matrices provided 
better fit to Korsmeyer-Peppas model (Tables 5 
and 6). No formulation fitted to Higuchi 
equation, demonstrating that MEX release 
mechanism was not a diffusion process 
dependent on the square root of time.  
The formulations containing PEO 
demonstrated also a good fit to zero-order 
kinetics. The exponent Ƞ calculated (Tables 5 
and 6) for Korsmeyer-Peppas equation 
confirmed this to PEO N60K (Ƞ between 0.94 
and 1.0) and to PEO 301 (Ƞ about 0.87), 
indicating super case-II and case-II transport 
mechanism, respectively, as also evidenced by 
quasi-linear release profiles (Figures 4 and 5). 
HPMC K100LV formulations demonstrated a 
similar release profile to PEO N60K, where a 
super case-II transport mechanism was obtained 
due to the dissolution of polymeric matrix and 
relaxation of the polymer chain, with zero-order 
release.  
Based on the dissolution profiles, HPMC 
K100LV 30%, HPMC K4M 20%, PEO N60K 
20%, and PEO N60K 30% matrices presented a 
combination of polymer type, MW, 
concentration, and complete drug release that 
could result in a formulation able to resist to the 
destructive forces within the gastrointestinal 
tract, providing a superior in vivo performance. 
In fact, the results obtained confirm that gels 
showing lower strength and texture, usually 
derived from low MW polymers, have lower 
resistance to the fluid erosion action and the 
release of the active molecule is mainly due to 
polymer relaxation and chains disentanglement, 
leading to drug delivery kinetic towards an 
erosion/relaxation mechanism, with exponent Ƞ 
≥ 0.89. On the other hand, when the MW or 
polymer concentration is increasing, the gel 
layer formed will be concomitantly characterized 
by higher strength and consistence, being less 
susceptible to erosion and chains 
disentanglement, with drug release mechanism 
tending to diffusion (with decreasing exponent Ƞ 
values).  
For quinolones, the activity is partly related 
to the ratio between the serum peak 
concentration and the minimum inhibitory 
concentration of the offending organism (24, 
51). This way, together with in vitro dissolution 
analysis, in vivo bioavailability studies are 
critical to obtain a formulation with the desired 
pharmacokinetic and toxicity profiles. A 
successful example of a commercially available 
quinolone extended-release dosage forms is 
ciprofloxacin (1000mg) extended-release tablets. 
Compared to the immediate-release (500 mg, 
twice-daily administration), the ER formulation 
provided higher maximum plasma 
concentrations with lower interpatient 
variability, with the therapeutic drug levels being 
achieved rapidly and maintained over the course 
of 24 h, with good tolerability, and safety (52–
54). After a complete formulation development, 
the final extended-release MEX dosage form 
could be a convenient, well-tolerated and 
effective therapy mainly for urinary tract 
infections that may improve patients’ 
compliance with treatment and thus decrease the 
risk of treatment failure and the spread of 
antibiotic resistance, being an alternative to the 
commercially available ciprofloxacin extended-
release tablets.  
Table 5 Coefficients of determination (𝑟2) obtained from dissolution of Meropenem uncoated 
formulations according to different mathematical models. 
















HPMC K100LV 20%  0.9794  0.9247  0.9685  0.9952  0.9623 
HPMC K100LV 30% 0.9794  0.8538  0.9681  0.9985  0.9761 
HPMC K4M 20%  0.9943 0.9916  0.9604  0.9963  0.7115 
HPMC K4M 30% 0.9834 0.9954 0.9801 0.9986 0.6593 
PEO N60K 20%  0.9976 0.9302 0.9372 0.9994 0.9485 
PEO N60K 30%  0.9978 0.9513 0.9127 0.9990 1.0027 
PEO 301 20%   0.9978  0.9591 0.9180 0.9978 0.8900 
PEO 301 30%  0.9978 0.9795 0.9308 0.9971 0.8771 
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Table 6 Coefficients of determination (𝑟2) obtained from dissolution of meropenem coated 
formulations according to different mathematical models. 

















HPMC K100LV 20%  0.9827  0.9719  0.9649  0.9990  0.9283 
HPMC K100LV 30% 0.9898  0.9571  0.9588  0.9999  0.8867 
HPMC K4M 20%  0.9833 0.9981  0.9807  0.9998  0.7270 
HPMC K4M 30% 0.9784  0.9921  0.9821  0.9984  0.7041 
PEO N60K 20%  0.9759  0.9716  0.9685  0.9975  0.9892 
PEO N60K 30%  0.9955  0.9766  0.9468  0.9992  1.0019 
PEO 301 20%  0.9970  0.9593  0.9277  0.9979  0.8522 
PEO 301 30%  0.9911  0.9586  0.9216  0.9917  0.8550 
4. Conclusion 
In this study, the development of a stable 
extended-release dosage form containing 
meropenem was demonstrated. The film-coating 
of tablets was necessary to avoid a photo 
induced color changing of the active 
pharmaceutical ingredient. The dissolution 
studies showed that according to the increase in 
polymer molecular weight and concentration, the 
matrix changed from a more erodible system 
(with zero-order release) to a system with 
dissolution controlled by drug diffusion and 
polymer relaxation/erosion mechanisms. The 
formulations containing intermediate molecular 
weight HPMC or PEO or high concentration 
(30%) of low molecular weight polymers 
(HPMC K100LV 30%, HPMC K4M 20%, PEO 
N60K 20%, and PEO N60K 30%) are more 
promising, since a combination between gel 
structure and complete in vitro drug release was 
obtained. This prolonged and complete in vitro 
release profile is expected to lead to an increased 
bioavailability; however, in vivo studies are 
necessary to confirm this possibility. Based on 
an improved bioavailability combined with a 
reduced frequency of administration, an 
improved patient compliance and decreased 
bacterial resistance could be achieved. 
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